RTW Investments LP boosted its holdings in shares of Viveve Medical Inc (NASDAQ:VIVE) by 42.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,480,565 shares of the company’s stock after buying an additional 1,333,333 shares during the period. RTW Investments LP owned about 14.21% of Viveve Medical worth $4,705,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Geode Capital Management LLC boosted its stake in Viveve Medical by 13.6% during the fourth quarter. Geode Capital Management LLC now owns 216,566 shares of the company’s stock worth $227,000 after buying an additional 25,975 shares in the last quarter. Sargent Investment Group LLC acquired a new stake in shares of Viveve Medical in the 4th quarter valued at $32,000. Bank of New York Mellon Corp boosted its stake in shares of Viveve Medical by 266.6% in the 4th quarter. Bank of New York Mellon Corp now owns 45,223 shares of the company’s stock valued at $47,000 after purchasing an additional 32,888 shares in the last quarter. Finally, Nantahala Capital Management LLC boosted its stake in shares of Viveve Medical by 66.7% in the 4th quarter. Nantahala Capital Management LLC now owns 6,581,465 shares of the company’s stock valued at $6,911,000 after purchasing an additional 2,633,333 shares in the last quarter. Hedge funds and other institutional investors own 89.64% of the company’s stock.

Shares of NASDAQ:VIVE traded up $0.02 on Monday, hitting $0.97. The stock had a trading volume of 17,811 shares, compared to its average volume of 151,172. The company has a debt-to-equity ratio of 6.21, a quick ratio of 3.51 and a current ratio of 3.89. Viveve Medical Inc has a twelve month low of $0.87 and a twelve month high of $4.34. The company has a market capitalization of $44.04 million, a PE ratio of -0.46 and a beta of 0.71.

Several brokerages have recently commented on VIVE. Raymond James reduced their target price on shares of Viveve Medical from $4.50 to $3.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 12th. Craig Hallum set a $1.00 target price on shares of Viveve Medical and gave the company a “hold” rating in a research note on Friday, January 18th. Maxim Group restated a “buy” rating on shares of Viveve Medical in a research note on Thursday, January 17th. Finally, Mizuho restated a “buy” rating and issued a $4.00 target price on shares of Viveve Medical in a research note on Friday, March 15th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $4.00.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.dailypolitical.com/2019/03/25/rtw-investments-lp-acquires-1333333-shares-of-viveve-medical-inc-vive.html.

Viveve Medical Profile

Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable accessories.

Further Reading: How to calculate compound interest

Institutional Ownership by Quarter for Viveve Medical (NASDAQ:VIVE)

Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.